ERBB3 blockade sensitizes HCC to regorafenib after first-line TKI resistance by inhibiting HIF1A-ABCB1 signaling.

seribantumab (MM-121) - Elevation Oncology

sorafenib - Generic mfg.

Lenvima (lenvatinib) - Eisai, Merck (MSD)

Stivarga (regorafenib) - Bayer

http://www.ncbi.nlm.nih.gov/pubmed/41555547

Baorui Tao; Bo Zhang; Chenhe Yi; Jing Lin; Jinhong Chen; Rongquan Sun; Xiangyu Wang; Yan Geng; Yinchen Gu

Jan 20, 2026